A Clinical Pharmacological Study of Intravenous Administration of Vesicular Stomatitis Oncolytic Virus Injection (Revottack）Combined PD-1 Inhibitor in Patients With Advanced Malignant Solid Tumor
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 入组人数
- 10
- 试验地点
- 1
- 主要终点
- Incidence of adverse events
研究概览
简要总结
This is a one arm, open clinical pharmacological exploration study initiated by researchers to evaluate the safety and effectiveness of vesicular stomatitis oncolytic virus injection (Revottack) combined with PD-1 inhibitor in patients with advanced malignant solid tumors.
The purpose of this study is to evaluate the safety, tolerability, anti-tumor activity, immunogenicity, immune response, pharmacokinetic (PK) characteristics and shedding characteristics of Revottack injection combined with PD-1 inhibitor in patients with advanced solid tumors.
详细描述
This is a one arm, open clinical pharmacological exploration study initiated by researchers to evaluate the safety and effectiveness of vesicular stomatitis oncolytic virus injection (Revottack) combined with PD-1 inhibitor in patients with advanced malignant solid tumors.
This study is planned to enroll 6-10 patients with advanced solid tumors. Subjects will receive the administration of revottack and PD-1( Toripalimab)inhibitor at a given time.
The purpose of this study is to evaluate the safety, tolerability, anti-tumor activity, immunogenicity, immune response, pharmacokinetic (PK) characteristics and shedding characteristics of Revottack injection combined with PD-1 inhibitor in patients with advanced solid tumors.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •The age at the time of signing the informed consent is ≥ 18 years old, regardless of gender;
- •Patients with advanced malignant solid tumor confirmed by histology or cytology; Failure in standard treatment (disease progression or intolerable treatment after treatment) and no effective treatment means, or no standard treatment scheme, or inability to obtain standard treatment due to objective conditions.
- •According to RECIST 1.1, there is at least one assessable tumor focus with the longest diameter ≥ 10mm (if it is a malignant lymph node, the short diameter ≥ 15mm is required);
- •ECOG physical strength score 0-2;
- •Full organ function:
- •Blood system (no blood transfusion or hematopoietic stimulator treatment within 14 days) Absolute neutrophil count (ANC) ≥ 1.5 × 109/L Platelet (PLT) ≥ 75 × 109/L Hemoglobin (Hb) ≥ 80g/L Lymphocyte absolute value (LYM) ≥ 0.8 × 109/L liver function Total bilirubin (TBIL) ≤ 1.5 × ULN Alanine aminotransferase (ALT) ≤ 3 × ULN (Patients with liver metastasis or liver cancer: ≤ 5 × ULN ) Aspartate aminotransferase (AST) ≤ 3 × ULN (Patients with liver metastasis or liver cancer: ≤ 5 × ULN) renal function Creatinine clearance rate (Ccr) > 50ml/min/1.73m2 (calculated according to Cockcroft Gault formula) Coagulation function test Activated partial thromboplastin time (APTT) ≤ 1.5 × ULN International normalized ratio (INR) ≤ 1.5 × ULN
- •Eligible patients (male and female) with fertility must agree to work in Revottack Use reliable contraceptive methods (hormone or barrier method or abstinence) within 6 months after injection; The blood pregnancy test of female patients of childbearing age must be negative within 7 days before enrollment;
- •Subjects must give informed consent to the study before the study, and voluntarily sign a written informed consent form.
排除标准
- •Patients with active CNS metastasis and/or carcinomatous meningitis are known or found during screening. However, the following subjects are allowed to be included in the group: ① Patients with asymptomatic brain metastasis (that is, patients without progressive central nervous system symptoms caused by brain metastasis do not need to use corticosteroids) can participate. ② Subjects who had been treated and had stable brain metastases for at least 2 months had no evidence of new or expanded brain metastases.
- •He received chemotherapy, radiotherapy, biological therapy, endocrine therapy, targeted therapy, immunotherapy and other anti-tumor treatments within 2 weeks before the first use of the study drug;
- •Participated in other unlisted clinical studies within 4 weeks before the first use of the study drug;
- •Major organ surgery (excluding puncture biopsy) or significant trauma occurred within 4 weeks before the first use of the study drug, or major elective surgery required during the study period.
- •Patients who received systemic corticosteroids (prednisone>10mg/day or equivalent dose of the same drug) or other immunosuppressants within 14 days before the first use of the study drug; The following cases are excluded: local, eye, intra articular and intranasal corticosteroids are used for treatment; Short term use of corticosteroids for prevention and treatment;
- •Have received other oncolytic virus treatment within 8 weeks before the first use of the study drug;
- •Any vaccine was inoculated within 7 days before the first use of the study drug;
- •Antiviral drugs were used within 2 weeks before the first use of the study drug, and long-acting interferon was used within 4 weeks;
- •The adverse reaction of previous anti-tumor treatment has not recovered to ≤ 1 level (except for the toxicity judged by the researcher as no safety risk, such as alopecia, hypothyroidism stabilized by hormone replacement therapy, etc.);
- •Uncontrolled active infection exists, which may seriously affect the efficacy and safety evaluation as judged by the researcher;
- •Have a history of immunodeficiency, including HIV antibody test positive;
- •Active hepatitis B (HBsAg positive and HBV DNA>the lower detection limit of the research center), or hepatitis C virus infection (anti HCV positive or HCV RNA positive), or syphilis infection;
- •Cardiovascular and cerebrovascular diseases shall conform to any of the following:
- •Poor control of hypertension (systolic blood pressure ≥ 150 mmHg or diastolic blood pressure ≥ 100 mmHg);
- •Cardiac function ≥ Grade 2 congestive heart failure (NYHA classification);
- •Arrhythmias requiring clinical intervention (including QTc ≥ 450ms (male) and QTc ≥ 470ms (female));
- •Serious arteriovenous thromboembolism events, including myocardial infarction, unstable angina, cerebrovascular accident or transient ischemic attack, pulmonary embolism, deep vein thrombosis or any other serious thromboembolism;
- •The third space effusion that cannot be controlled clinically is not suitable to be included in the group according to the judgment of the researcher;
- •Patients with active or ever suffered from autoimmune diseases that may recur (such as systemic lupus erythematosus, rheumatoid arthritis, vasculitis, etc.), except patients with clinically stable autoimmune thyroiditis;
- •Known alcohol or drug dependence;
- •Mental disorders or poor compliance;
- •Pregnant or lactating women;
- •The investigator believes that the subject is not suitable to participate in this clinical study because of other serious systemic diseases or other reasons.
结局指标
主要结局
Incidence of adverse events
时间窗: Up to 6 months
Graded according to the NCI CTCAE version 5.0.
Objective response rate
时间窗: Up to 2 years
Assess the proportion of patients who achieved complete or partial response
The changes from baseline of lymphocyte counts
时间窗: Up to 28 days
The changes from baseline of Peripheral blood lymphocyte subtypes counts
The concentration of antiviral antibody
时间窗: Up to 22 Weeks
The concentration of antiviral antibody of Revottack in blood
The rate of subjects with viral shedding of Revottack
时间窗: Up to 22 Weeks
The rate of subjects with viral RNA in the secretion
Disease control rate
时间窗: Up to 2 years
Assess the proportion of patients who achieved complete or partial or stable response
The Tmax of Viral RNA in blood
时间窗: Up to 22 Weeks
Time to peak viral RNA concentration
The Cmax of Viral RNA in blood
时间窗: Up to 22 Weeks
The peak viral RNA concentration
次要结局
未报告次要终点